Narrative review of the clinical safety of MenACYW-TT: a quadrivalent meningococcal vaccine conjugated to tetanus toxoid licensed in the US and abroad.

Olga Syrkina¹, Mary Bausch-Jurken², Arlette Delgado³, Jelena Jovanovic⁴, Corwin A Robertson⁵

¹Patient Safety and Pharmacovigilance - Vaccines, Sanofi, Cambridge, MA, USA.

²North America Medical Affairs - Vaccines, Sanofi, Morristown, NJ, USA.

³Patient Safety and Pharmacovigilance - Vaccines, IQVIA, Madrid, Spain.

⁴Patient Safety and Pharmacovigilance - Vaccines, IQVIA, Belgrade, Serbia.

⁵Global Medical Affairs - Vaccines, Sanofi, Morristown, NJ, USA.

PubMed DOI

Abstract

INTRODUCTION: Routine meningococcal vaccination campaigns have substantially reduced the burden of invasive meningococcal disease in pediatric individuals, leading to relative increases in burden in older age groups. There is a need for safe, effective meningococcal vaccines that can be used across broad age ranges. MenACYW-TT, a quadrivalent tetanus-toxoid-conjugate meningococcal vaccine indicate…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.